Get the Stockscreener App
90.78
4.36%
3.79
After Hours:
90.60
-0.18
-0.20%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $90.78, with a volume of 14.14M.
It is up +4.36% in the last 24 hours and up +3.70% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$86.99
Open:
$89.32
24h Volume:
14.14M
Relative Volume:
1.14
Market Cap:
$158.12B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
25.29
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
+5.19%
1M Performance:
+3.70%
6M Performance:
-27.61%
1Y Performance:
-31.72%
1-Day Range:
$89.20
$91.48
1-Week Range:
$85.28
$91.48
52-Week Range:
$81.97
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
90.78 | 151.52B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.21 | 113.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
81.93 | 100.08B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
48.85 | 70.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.45 | 49.52B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Judge Questions Fees In Abbott Investors' $40M Formula Deal - Law360
Abbott Can’t Drop PediaSure Children’s Growth Deception Suit - Bloomberg Law News
Abbott Labs must face lawsuit over PediaSure children's growth claims - Reuters
Is It Too Late to Buy Abbott Laboratories (ABT) After 4.4% Rally? GF Value Says Undervalued - GuruFocus
Abbott Labs must face lawsuit over PediaSure children’s growth claims - The Mighty 790 KFGO
Abbott Laboratories Stock (ABT) Closed Up by 4.18% on Jun 4: Drivers Behind the Movement - TradingKey
Abbott Laboratories stock (US0028241000): shares advance on strong US trading - AD HOC NEWS
[Latest] Non-Invasive Blood Glucose Monitoring Devices Market Size to Hit USD 340.49 Million with a Promising CAGR of 25.60% by 2034 - GlobeNewswire Inc.
Abbott shares rise as investors refocus on diabetes tech and cancer-diagnostics momentum - Quiver Quantitative
Abbott Addresses a Major Diabetes Care Gap With Tech Innovation - Zacks Investment Research
Jim Cramer Says “No One Disputes the Science and Commercial Smarts of Abbott” - Insider Monkey
Abbott Pakistan’s profit surge masks a volume problem - Profit by Pakistan Today
Assessing Abbott Laboratories (ABT) Valuation After New Diabetes Sensor And Cancer Screening Tailwinds - Yahoo Finance
Abbott Laboratories stock (US0028241000): U.S. healthcare name steadies after recent slide as instit - AD HOC NEWS
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't - The Motley Fool
Is Abbott Laboratories stock underperforming the Dow? - MSN
MiniMed Shares Rise on 4Q Sales, Abbott Partnership Expansion - marketscreener.com
Abbott (ABT) Expands Collaboration with MiniMed for Innovative G - GuruFocus
Abbott Laboratories stock is getting decimated, but the smart money senses opportunity - MSN
MiniMed partners with Abbott on dual glucose-ketone sensors By Investing.com - Investing.com Canada
Abbott Laboratories Deadline Alert - TMX Newsfile
Abbott India Ltd. Faces Bearish Momentum Amid Technical Downgrade - Markets Mojo
How A Steady Valuation Is Shaping The Evolving Abbott Laboratories (ABT) Investment Story - Yahoo Finance
Abbott Laboratories stock (US0028241000): shares edge higher ahead of Q2 2026 earnings after guidanc - AD HOC NEWS
Is Abbott Laboratories (ABT) Now Attractive After A 33% One Year Share Price Slide - simplywall.st
Why Investors Are Cautious on Abbott Laboratories (ABT) - Insider Monkey
Why Investors Are Cautious on Abbott Laboratories (ABT)? - Yahoo Finance
The demand for healthcare is going to continue to accelerate, says Abbott Labs CEO Robert Ford - MSN
Peripheral Vascular Devices Market by Type, End User - GlobeNewswire Inc.
Abbott Labs Spinal Cord Device Causes Shocks, Suit Claims - Law360
Tax Havens Cost US $40 Billion After Trump Withdraws From Global Deal - The Fiscal Times
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Goldman Sachs Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $113 - Moomoo
Abbott Laboratories stock (US0028241000): shares steady after CE mark win for Libre Duo system - AD HOC NEWS
Precision Trading with Abbott Laboratories (ABT) Risk Zones - Stock Traders Daily
Abbott's CE Mark Win for Libre Duo Systems May Lift Its Stock - Yahoo Finance Australia
Ophthalmology Devices Market Is Going to Boom | Abbott Laboratories, Carl Zeiss AG, CooperVision - openPR.com
Abbott Accused of Firing Manager for Reporting Kickback Schemes - Bloomberg Law News
Abbott Laboratories: Buy Rating Reaffirmed on Improving 2026 Growth Outlook and Margin Expansion Potential, with Price Target Trimmed to $113 - TipRanks
Abbott Laboratories (ABT) Stock Analysis: Exploring a 37% Upside Potential Amidst Healthcare Innovations - DirectorsTalk Interviews
Abbott Laboratories stock (US0028241000): U.S. healthcare name steadies after recent ETF inclusion a - AD HOC NEWS
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
ACS Guideline Reaffirmation Anchors Abbott Laboratories Cancer Screening Strategy - sekbernews.id
Does ACS Endorsement of Cologuard Shape the Bull Case for Abbott Laboratories (ABT) in Cancer Screening? - simplywall.st
Abbott Laboratories stock (US0028241000): Insider activity stays in focus - AD HOC NEWS
Is ACS’s Cologuard Endorsement Reshaping the Investment Case for Abbott Laboratories (ABT)? - Yahoo Finance
Abbott Laboratories (ABT) Slips 0.7% as Resistance Holds FirmDemand Zone - thelegaladvocate.com
Trump Clears Way for Companies to Avoid Taxes in Havens Including Malta and Cyprus - The New York Times
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $115 - Moomoo
BSX vs. ABT: Which Medical Stock Has More Upside Potential? - TradingView
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):